Instead, this paper focuses on Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) as commonly used anti-obesity medications (AOMs) and summarizes the current evidence on their efficacy and safety, particularly from the perspective of sarcopenia in older adults
March 28, 2025 Update: Plaintiffs in the GLP-1 drug litigation formally opposed efforts by drug manufacturers to dismiss most claims in the consolidated master complaint
Compounded tirzepatide is prepared per individual prescription and is not itself FDA-approved as a drug
A clean, organized process leads to clean, reliable data
However, GLP-1 drugs are not approved for cancer prevention
Along this line, because of synergistic effects between NAMPT and HDAC inhibitors, dual NAMPT/HDAC inhibitors have been developed and have shown good efficacy in vitro